Merck Completes Adult Enrollment in Two Phase 3 Alimatravir HIV Prevention Studies
Merck completed adult enrollment in two Phase 3 studies of alimatravir for monthly HIV prevention.
Merck completed adult enrollment in two Phase 3 studies of alimatravir for monthly HIV prevention.